SignalTrace

Tirzepatide — T2D Clinical Evidence

John Montgomery11 min read

tirzepatide — Vault Index

Research Goal

Build a fact-first medical evidence vault on Tirzepatide / Mounjaro for Type 2 Diabetes (2018–2026), separating clinical diabetes evidence from weight-loss marketing, with special focus on HbA1c reduction, insulin-use reduction, advanced T2D, kidney outcomes, circulation claims, side-effect rates, patient feedback, and missing long-term evidence in patients aged 50+.

Sources: PubMed, NEJM, Lancet, JAMA, BMJ, Diabetes Care, Nature Medicine; ClinicalTrials.gov; FDA/EMA/MHRA regulatory documents; ADA/EASD/NICE/KDIGO guidelines; real-world evidence studies; patient feedback from Drugs.com, WebMD, Reddit, and HealthUnlocked (anecdotal — labelled as such).

Iterations completed: 17 / 15 | Vault status: Complete (2 post-cap supplementary rounds)

Final Report

A complete evidence summary across 16 research iterations — domain verdicts with key numbers, safety profile, confirmed evidence gaps, and the SGLT2i comparison. All sources are primary literature (NEJM, Lancet, JAMA, BMJ, FDA, NICE). Observational data is distinguished from RCT evidence throughout.

→ Read the full Final Report

What This Vault Is About

This knowledge vault was built to answer one practical question honestly: what does the science actually show about tirzepatide (Mounjaro) for people with Type 2 Diabetes, setting aside the marketing? The research ran for 15 iterations across 71 notes, drawing on Phase 3 clinical trials, cardiovascular outcomes data, guideline recommendations, meta-analyses, and real-world patient registry studies published between 2018 and 2026. The core commitment throughout was to keep T2D evidence separate from obesity evidence — the SURPASS trial programme (T2D patients) is the primary evidence base; the SURMOUNT programme (obesity without T2D) is clearly labelled as context only.

The headline finding is that tirzepatide is the most effective glucose-lowering drug currently approved for T2D, reducing HbA1c by 1.87–2.58% in absolute terms — consistently beating both semaglutide (Ozempic) and basal insulin in every head-to-head trial. A meaningful proportion of T2D patients (13–62% depending on dose and baseline) achieve HbA1c below 5.7%, which is normal blood sugar range. This is pharmacological control, not a cure — glycaemic benefits reverse within weeks of stopping, which is one of the vault’s key clinical caveats. Alongside glycaemic control, the trials show weight loss of 7–14 kg in T2D patients, near-elimination of hypoglycaemia compared to insulin, eGFR preservation in patients with stage 3 CKD, a 46% reduction in worsening heart failure events in the HFpEF+obesity subgroup, and dramatic reduction in sleep apnoea severity. Real-world registry data from US electronic health records confirms these trial-level results translate to clinical practice.

The vault is equally candid about what the evidence does not show. Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT, 2025) demonstrated it is at least as cardioprotective as dulaglutide — a non-inferiority result, not a proven reduction in heart attacks versus placebo. There is no safety data whatsoever for patients with advanced kidney disease (eGFR below 30), despite these being the highest-risk T2D patients — they were excluded from every SURPASS trial. Long-term outcomes beyond two years in T2D are largely unknown. The stopping problem is underappreciated: tirzepatide does not modify the underlying disease — once the drug is removed, the disease reasserts itself rapidly. Patients and health systems need to plan for indefinite treatment, with all the cost and access implications that carries. The UK-specific section is particularly honest about NHS access barriers: the rolling 12-year obesity prescribing plan, patchy GP knowledge of the TA924 T2D indication, and an emerging patient-reported signal that thyroid hormone doses may need adjustment after starting tirzepatide.

Seed entities (round 1)

  • HbA1c Reduction — Tirzepatide consistently reduces HbA1c by 1.87%–2.58% in T2D Phase 3 trials, superior to semaglutide and basal insulin in head-to-head co…
  • Insulin-Use Reduction — Tirzepatide avoids need for insulin initiation in pre-insulin T2D (SURPASS-3/-4) and can replace prandial insulin intensification in pati…
  • Kidney Outcomes — Post-hoc SURPASS-4 analysis shows tirzepatide nearly halved composite kidney risk vs insulin glargine; dedicated powered CKD trial does n…
  • SURPASS Clinical Trial Programme — Six Phase 3 RCTs forming the SURPASS programme (2019–2023) establishing tirzepatide’s efficacy and safety in T2D across disease stages, a…
  • SURPASS-1 — Phase 3 RCT of tirzepatide monotherapy vs placebo in T2D; HbA1c fell 1.87–2.07% vs +0.04% placebo at 40 weeks with no severe hypoglycaemia.
  • SURPASS-2 — Phase 3 RCT: tirzepatide 5/10/15mg vs semaglutide 1mg on metformin; all tirzepatide doses superior for HbA1c reduction (−0.15% to −0.45%…
  • SURPASS-4 — Phase 3 RCT: tirzepatide vs insulin glargine in T2D with high CV risk; tirzepatide superior for HbA1c (−2.43%/−2.58% vs −1.44%) with lowe…
  • SURPASS-6 — Phase 3b RCT: tirzepatide vs prandial insulin lispro (both on basal insulin) in T2D; tirzepatide superior (HbA1c 6.7% vs 7.7%) with 11× l…
  • Insulin Glargine — Long-acting basal insulin analogue; comparator in SURPASS-4 and SURPASS-3; tirzepatide superior on HbA1c, weight, hypoglycaemia, and kidn…
  • Insulin Lispro — Rapid-acting prandial insulin analogue; comparator in SURPASS-6; tirzepatide superior with dramatically lower hypoglycaemia (0.4 vs 4.4 e…
  • Type 2 Diabetes — Chronic metabolic disease of impaired insulin secretion and insulin resistance, managed through stepwise therapy escalation from oral age…
  • Dedicated CKD Outcome Trial — No dedicated powered CKD outcome trial exists for tirzepatide as of 2024; kidney protection claims rely entirely on post-hoc analyses of…
  • GLP-1 Receptor Agonism — GLP-1 receptor activation drives insulin secretion, glucagon suppression, appetite reduction, and GI effects in tirzepatide; shared with…
  • Tirzepatide — Dual GIP/GLP-1 receptor agonist (tirzepatide) approved for T2D and obesity; once-weekly subcutaneous injection; strongest HbA1c and weigh…
  • Hypoglycaemia Risk — Tirzepatide has very low intrinsic hypoglycaemia risk (glucose-dependent mechanism); far lower than insulin comparators; risk rises with…
  • Nausea and Vomiting Risk — Nausea (12–26%) and vomiting (2–13%) are tirzepatide’s most common adverse events; dose-dependent; peak during escalation; comparable to…

ClinicalOutcomes (researched — round 2)

  • Circulation Claims — No direct evidence of ‘improved blood circulation’ from tirzepatide trials; indirect evidence from ICAM-1/hsCRP biomarker reduction and c…

ClinicalOutcomes (researched — round 4)

  • Cardiovascular Risk — SURPASS-CVOT (NEJM 2025): tirzepatide noninferior to dulaglutide (HR 0.92) for 3-point MACE in T2D+ASCVD; 4-point MACE-4 significantly re…

ClinicalOutcomes (researched — rounds 8–9)

  • Heart Failure Outcomes — SUMMIT trial (NEJM 2024, n=731): tirzepatide reduces worsening HF events by 46% in HFpEF+obesity; LV mass and paracardiac adipose tissue…
  • MASLD NAFLD Outcomes — SYNERGY-NASH Phase 2 (NEJM 2024): tirzepatide significantly resolves MASH (up to 73%) without worsening fibrosis; Phase 3 needed; SURPASS…

ClinicalOutcomes (researched — round 13)

  • Real-World Evidence T2D — US real-world T2D studies confirm trial-level HbA1c and weight reductions; tirzepatide favoured over semaglutide; GLP-1 RA naïve patients…

ClinicalOutcomes (stubs — round 1)

  • Albuminuria — Albuminuria (UACR) is a marker of kidney damage; tirzepatide reduces UACR −6.8% to −26.3% vs comparators across SURPASS analyses; reducti… (stub)
  • Weight Loss in T2D — Body weight reduction in T2D patients on tirzepatide — 7–14 kg across SURPASS trials; partially confounds HbA1c and kidney outcome improv… (stub)

ClinicalTrials (researched — rounds 4–5)

  • SURPASS-3 — SURPASS-3 (Lancet 2021, n=1444): tirzepatide superior to insulin degludec for HbA1c (−1.93 to −2.37% vs −1.34%) and weight (−7.5 to −12.9…
  • SURPASS-CVOT — SURPASS-CVOT (NEJM 2025, n=13,299): tirzepatide noninferior to dulaglutide for 3-point MACE in T2D+ASCVD; expanded MACE-4 significantly r…

ClinicalTrials (researched — round 8)

  • SURPASS-5 — SURPASS-5 (JAMA 2022, n=475): tirzepatide add-on to basal glargine; HbA1c −1.87 to −2.40% vs −0.86% placebo; 85–90% reached <7%; weight −…

ClinicalTrials (researched — rounds 10–11)

  • SURMOUNT-5 — SURMOUNT-5 (NEJM 2025, n=751): tirzepatide -20.2% vs semaglutide 2.4mg -13.7% weight loss in obesity without T2D at 72 weeks — tirzepatid…
  • SURMOUNT-OSA — SURMOUNT-OSA (NEJM 2024, n=469): tirzepatide reduces AHI ~20-24 events/h vs placebo in moderate-to-severe OSA + obesity at 52 weeks; all…

ClinicalTrials (stubs — round 11)

  • TREASURE-CKD — Ongoing Eli Lilly trial (NCT05536804) of tirzepatide in overweight/obesity and CKD ±T2D; designed to assess kidney function effects; firs… (stub)

ClinicalTrials (stubs — rounds 15–16)

  • Placebo — Placebo comparator used in SURPASS-1, SURPASS-5 (add-on to insulin), and SURMOUNT trials; establishes absolute tirzepatide effect without… (stub)
  • SURMOUNT-MMO — Ongoing Eli Lilly CV outcomes trial of tirzepatide vs placebo in obesity+CVD (without T2D); first tirzepatide-vs-placebo MACE data expect… (stub)

Comparators (researched — round 10)

  • Semaglutide — GLP-1 RA (Novo Nordisk) — head-to-head comparator in SURPASS-2 (T2D) and SURMOUNT-5 (obesity); tirzepatide superior on weight and HbA1c i…

Comparators (researched — round 17)

  • SGLT2 Inhibitors — SGLT2i have dedicated powered kidney and CV outcomes trials (CREDENCE/DAPA-CKD/EMPA-KIDNEY HR 0.61–0.72 kidney; EMPA-REG MACE HR 0.86 pla…

Comparators (stubs — round 1)

  • Insulin Degludec — Ultra-long-acting basal insulin analogue (Novo Nordisk, Tresiba); comparator in SURPASS-3 vs tirzepatide on metformin; tirzepatide superi… (stub)

Comparators (stubs — round 15)

  • Dulaglutide — Once-weekly GLP-1 receptor agonist (Eli Lilly); active comparator in SURPASS-4 and SURPASS-CVOT; tirzepatide was non-inferior and numeric… (stub)

Conditions (stubs — round 11)

  • Obstructive Sleep Apnea — Common sleep disorder with intermittent upper-airway obstruction; strongly associated with obesity and T2D; tirzepatide reduces AHI ~20-2… (stub)

EvidenceGaps (researched — rounds 6–7)

  • Advanced T2D High-Dose Insulin — SURPASS-5/6 show tirzepatide benefit on basal insulin background; no specific data for TDD >80U or full basal-bolus with high insulin res…
  • Sarcopenia Risk in Older Adults — SURMOUNT-1 DXA: ~75% fat, ~25% lean of weight lost; lean mass ratio similar to other weight-loss modalities. Still no T2D-specific lean m…

EvidenceGaps (researched — round 11)

  • Tirzepatide in Advanced CKD — eGFR <30 excluded from all SURPASS trials — no trial data; FDA label allows use without dose adjustment (not renally cleared); eGFR prese…

EvidenceGaps (researched — round 14)

  • Older Adults T2D — SURPASS pooled subgroup (n=540, ≥65 BMI <30): HbA1c reduction and weight loss consistent with overall population; hypoglycaemia no worse;…
  • Stopping Effects and Treatment Dependence — Stopping tirzepatide causes rapid glycaemic rebound in T2D (4-week washout data) and >50% weight regain in obesity (SURMOUNT-4, 52 weeks)…

EvidenceGaps (researched — round 16)

  • Long-Term T2D Outcomes — SURPASS-4 104-week post-hoc confirms HbA1c sustained at 2 years; no T2D HbA1c data beyond 104 weeks; SURMOUNT-1 3-year obesity data sugge…

Guidelines (researched — rounds 2–3)

  • ADA Standards of Care 2023-2024 — ADA 2023 added tirzepatide to T2D guidelines; ADA 2025 explicitly names tirzepatide (with semaglutide) as preferred agents for T2D with o…
  • NICE Technology Appraisal TA924 — NICE TA924 (2023) recommends tirzepatide as alternative to GLP-1 RAs in T2D; third/fourth line in NHS; must show ≥1% HbA1c and ≥3% weight…

Guidelines (researched — rounds 6–7)

  • ADA EASD 2022 Consensus Report — ADA/EASD 2022: tirzepatide named as superior-efficacy GIP/GLP-1 RA; GLP-1 RA prioritised for T2D+CVD; SGLT2i for T2D+HF/CKD; weight manag…
  • KDIGO 2022 CKD Diabetes Guideline — KDIGO 2022: T2D+CKD algorithm — metformin → SGLT2i (1A, eGFR ≥20) → GLP-1 RA (1B) if targets not met; tirzepatide falls within GLP-1 RA c…

Mechanisms (researched — round 10)

  • Beta-Cell Function — Tirzepatide improves HOMA2-B and HOMA2-IR markers in T2D; 13-62% achieve HbA1c <5.7% in SURPASS trials, but glycaemic gains reverse on st…

Mechanisms (researched — round 12)

  • GIP Receptor Agonism — GIPR agonism adds adipose lipolysis, weight-independent insulin sensitivity improvement, and sustained beta-cell stimulation to tirzepati…

RiskProfiles (researched — rounds 2–3)

  • Gallbladder Disease — Composite gallbladder/biliary disease risk is statistically increased with tirzepatide vs placebo/basal insulin (RR 1.97), though absolut…
  • Gastroparesis and Delayed Gastric Emptying — Delayed gastric emptying is a pharmacological effect of tirzepatide via GLP-1 receptor agonism; clinical gastroparesis rates not separate…
  • Pancreatitis Risk — Pancreatitis risk is NOT significantly elevated with tirzepatide vs comparators in RCT meta-analyses (RR 1.46, CI 0.59–3.61); absolute ra…
  • Treatment Discontinuation — Tirzepatide discontinuation due to AEs is 3–10% (dose-dependent); highest at 15mg; primarily GI-related; higher than GLP-1 RAs and basal…

RiskProfiles (researched — round 5)

  • Diabetic Retinopathy Risk — Tirzepatide increases PDR risk in patients with pre-existing moderate-severe NPDR (OR 2.15); REDUCES DR risk in those without pre-existin…

RiskProfiles (researched — round 9)

  • Thyroid Carcinoma Warning — FDA boxed warning based on rodent C-cell data; human evidence does NOT confirm increased MTC risk — FAERS shows no signal; retrospective…

RiskProfiles (researched — round 16)

  • Drug Interactions — Tirzepatide not CYP-metabolised; FDA label: no PK change in ESRD; gastric emptying delay affects oral drug Cmax (acetaminophen -50% singl…

RiskProfiles (stubs — round 15)

  • Side Effects Profile — Overall tirzepatide adverse effect profile: GI effects dominate (nausea 12-18%, vomiting 5-9%, diarrhoea 12-17%); mostly mild-moderate an… (stub)

UserFeedback (researched — round 2)

  • Patient Feedback T2D Drugs.com WebMD — Drugs.com average 8.5/10; ~70% positive; common positives: appetite suppression, weight loss, HbA1c improvement; common negatives: nausea…

UserFeedback (researched — round 4)

  • Patient Feedback T2D Reddit — Reddit T2D feedback 2024-2025: strongly positive HbA1c and insulin reduction reports; major GI side effects at dose escalation; cost/acce…

UserFeedback (researched — round 12)

  • NHS Patient Experience UK — UK T2D patients on NHS Mounjaro report dramatic weight loss and HbA1c normalisation; access barriers significant — NICE TA924 T2D criteri…

Open Questions

Research, not medical advice

This vault is epistemic research compiled from primary clinical sources. It is not medical advice, diagnosis, or a treatment recommendation. Consult a qualified healthcare professional before making any decision about tirzepatide or any medication.

Graph View